The specific objectives of the Mayo Comprehensive Cancer Center over the next five years are the following: 1) To enhance programs of clinical cancer research with particular emphasis on continued multidisciplinary coordination and on close liaison with and involvement of laboratory scientists. 2) To improve the quality and expeditious conduct of clinical cancer research programs by establishing appropriate and cost-effective shared resources, e.g., Cancer Center Statistical Unit, Cancer Pharmacy Unit, Surgical Pathology Shared Resource. 3) To continue development of basic laboratory programs in cancer and promote a """"""""centerness"""""""" among our laboratories by establishing appropriate shared resources, e.g., flow cytometry, protein analysis, monoclonal antibodies, immunogenetic mouse colony. 4) To continue development of laboratory research programs which are in direct affiliation with clinical research programs and which serve as a functional interface between basic scientist and clinical scientist, e.g., the cancer pharmacology laboratory, the radiation biology laboratory, the cell culture laboratory. 5) To fulfill our role as a Comprehensive Cancer Center by expanding our clinical research boundaries to involve the major community cancer centers of our region. 6) To develop new clinical and laboratory research programs which are appropriate to the assets of our Center. To continue and increase our active participation in the national cancer program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-15
Application #
3101457
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
1988-03-01
Project End
1993-02-28
Budget Start
1988-03-03
Budget End
1989-02-28
Support Year
15
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567

Showing the most recent 10 out of 1129 publications